KALA BIO, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $1.75M, a 13400.00% increase year-over-year.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $54.00K, a 14.89% increase year-over-year.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $0.00.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $67.00K, a 1.47% decline from fiscal 2024.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $68.00K, a 47.83% increase from fiscal 2023.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $46.00K, a 84.56% decline from fiscal 2022.
- KALA BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $298.00K, a 77.71% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $1.75M 10-Q · filed 2026-05-15 | $1.81M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $67.00K 10-K · filed 2026-04-15 |
| 2025-09-30 | $54.00K 10-Q · filed 2025-11-19 | $67.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19 | $60.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $13.00K 10-Q · filed 2026-05-15 | $60.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $68.00K 10-K · filed 2026-04-15 |
| 2024-09-30 | $47.00K 10-Q · filed 2025-11-19 | $68.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $61.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $21.00K 10-Q · filed 2025-05-14 | $61.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $46.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $40.00K 10-Q · filed 2024-11-12 | $46.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $144.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $6.00K 10-Q · filed 2024-05-14 | $144.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $298.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $138.00K 10-Q · filed 2023-11-13 | $298.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.07M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $160.00K 10-Q · filed 2023-05-09 | $1.07M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $1.34M 10-K · filed 2023-03-03 |
| 2021-09-30 | $906.00K 10-Q · filed 2022-11-08 | $1.34M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.18M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $431.00K 10-Q · filed 2022-05-16 | $1.18M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.02M 10-K · filed 2022-03-29 |
| 2020-09-30 | $746.00K 10-Q · filed 2021-11-15 | $1.02M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $815.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $269.00K 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $545.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $545.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |